S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
Log in

NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

$16.97
+1.09 (+6.86 %)
(As of 01/28/2020 04:00 PM ET)
Today's Range
$15.95
Now: $16.97
$17.04
50-Day Range
$15.88
MA: $17.95
$19.65
52-Week Range
$3.92
Now: $16.97
$20.09
Volume1.01 million shs
Average Volume1.27 million shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.34 million
Book Value$3.02 per share

Profitability

Net Income$-178,410,000.00
Net Margins-909.24%

Miscellaneous

Employees332
Market Cap$1.07 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.


Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) posted its quarterly earnings results on Monday, November, 4th. The company reported ($0.67) EPS for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.17. The company earned $13.15 million during the quarter, compared to analyst estimates of $1.61 million. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. View Karyopharm Therapeutics' Earnings History.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

What price target have analysts set for KPTI?

6 brokers have issued 1-year target prices for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $37.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $22.33 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

What is the consensus analysts' recommendation for Karyopharm Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Has Karyopharm Therapeutics been receiving favorable news coverage?

Media stories about KPTI stock have trended positive this week, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Karyopharm Therapeutics.

Are investors shorting Karyopharm Therapeutics?

Karyopharm Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 9,570,000 shares, a decrease of 6.8% from the December 15th total of 10,270,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the short-interest ratio is presently 7.6 days. Approximately 17.2% of the company's stock are sold short. View Karyopharm Therapeutics' Current Options Chain.

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Micron Technology (MU), Exelixis (EXEL), Alibaba Group (BABA), Caladrius Biosciences (CLBS), Amarin (AMRN), Celgene (CELG) and GW Pharmaceuticals PLC- (GWPH).

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
  • Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.49%), Private Capital Advisors Inc. (0.17%), Campbell & CO Investment Adviser LLC (0.06%), First Midwest Bank Trust Division (0.04%) and SG Americas Securities LLC (0.01%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Private Capital Advisors Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Campbell & CO Investment Adviser LLC and SG Americas Securities LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $16.97.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $1.07 billion and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  748
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel